ABFM HALM common mistakes
ABFM HALM · Understand the traps and how to avoid them.
Choosing the most sensitive screening test rather than the guideline-endorsed one (e.g., picking CA-125 alone for ovarian screening, or PSA without shared decision-making framing) when the stem asks for the recommended preventive approach.
Candidates conflate 'best at detecting disease' with 'recommended by USPSTF/ACS/ACOG'; exam stems reward the guideline-recommended strategy including its age cutoffs and interval.
What to do instead
Before answering any screening item, recite the guideline source and its exact age range, interval, and grade; if two options are both 'sensitive', choose the one matching the stated guideline grade (A/B) and population.
Treating an elevated office blood pressure as hypertension and starting medication without confirming with out-of-office measurement.
White-coat and masked hypertension are heavily tested; candidates anchor on a single high reading and skip the confirmatory step the stem is probing.
What to do instead
For any new hypertension stem, first ask whether home BP monitoring or ambulatory BP monitoring has been done; only treat after confirmation unless BP is ≥180/120 or there is target-organ damage.
Intensifying glucose-lowering therapy without addressing the agent indicated for the patient's comorbidities (ASCVD, heart failure, CKD) or without deintensifying in an older patient with hypoglycemia risk.
Candidates default to metformin-then-add-insulin algorithms and ignore the organ-protection indications for SGLT2 inhibitors and GLP-1 receptor agonists, or ignore A1c targets stratified by age and frailty.
What to do instead
For each diabetes stem, list the patient's comorbidities first, then match the drug class to them; separately state the individualized A1c goal (e.g., <7% for most, <8% for frail elderly) before selecting therapy.
Labeling a respiratory presentation as asthma or COPD without confirming with spirometry, or misclassifying a fixed obstruction versus reversible obstruction.
Stems describe wheeze and dyspnea and candidates jump to the diagnosis by pattern recognition, missing the post-bronchodilator FEV1/FVC criterion the question is testing.
What to do instead
Always require spirometry with post-bronchodilator testing in the reasoning; state the FEV1/FVC threshold (<0.70 for COPD, reversibility ≥12% and 200 mL for asthma) explicitly before choosing management.
Starting a new antidepressant without screening for bipolar disorder, or failing to recognize that a positive PHQ-9 does not establish major depressive disorder.
Candidates treat screening scores as diagnoses and skip the mania/hypomania history and substance/medical mimics that change the medication choice.
What to do instead
For any depression stem, run a mandatory checklist: PHQ-9 severity, MDD criteria count, bipolar screen (MDQ or clinical), substance use, and medical causes; only then select an SSRI and note the need to reassess in 4-6 weeks.
Ordering imaging immediately for acute low back pain without red flags, or missing the red flags that mandate urgent imaging.
Candidates either over-image (defensive) or under-triage (miss cauda equina, malignancy, infection); the exam tests the red-flag threshold, not the imaging modality.
What to do instead
Memorize the red-flag list (age >50 with new pain, trauma, fever, IV drug use, cancer history, neuro deficits, bowel/bladder changes, night pain); if none present, recommend conservative care and no imaging for 4-6 weeks.
Managing abnormal uterine bleeding or a positive cervical cancer screen without applying the age-specific and risk-specific algorithm (e.g., reflex HPV testing versus colposcopy thresholds).
Candidates memorize 'abnormal Pap = colposcopy' and miss the ASCCP risk-based triage that depends on HPV status, age, and prior history.
What to do instead
For each cervical screening stem, state the patient's age, HPV result, and prior screening history, then apply the risk-based management table; for AUB, first exclude pregnancy and stratify by age (<45 vs ≥45) before imaging or biopsy.
Deferring or omitting the prostate cancer screening discussion, or treating an elevated PSA as diagnostic without the confirmatory pathway.
Candidates either skip shared decision-making (tested as the correct answer for ages 55-69) or jump to biopsy without repeat PSA, free PSA, or risk calculator steps.
What to do instead
For prostate stems, state the age and risk group, document shared decision-making for ages 55-69 (earlier for high-risk), and for elevated PSA outline repeat testing, DRE, and risk-stratified next steps before biopsy.
Applying adult targets to older adults with multimorbidity (e.g., tight A1c, intensive BP, or polypharmacy review omitted) or missing deprescribing opportunities.
Candidates carry adult guidelines into geriatric stems and fail to individualize goals, screen for falls, cognition, and function, or recognize Beers criteria medications.
What to do instead
For every geriatric stem, first state functional status and life expectancy, then set individualized targets, screen for falls/cognition/polypharmacy, and explicitly identify any Beers-listed drug to deprescribe.
Missing the developmental and safety context in pediatric stems (e.g., not adjusting for age in fever workup, not screening for lead, or not recognizing vaccine schedule timing) and failing to apply the age-specific milestone or dosing.
Candidates apply adult thresholds to children or forget that the well-child visit bundles screening, immunizations, and anticipatory guidance that the question is testing.
What to do instead
For pediatric stems, anchor on age in months/years, state the well-child schedule item being tested (lead at 12 and 24 months, autism at 18 and 24 months, anemia at 12 months), and use weight-based dosing and age-specific fever thresholds before answering.